Capital Management Corp VA Sells 4,660 Shares of Supernus Pharmaceuticals, Inc. (SUPN)

Capital Management Corp VA reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 117,000 shares of the specialty pharmaceutical company’s stock after selling 4,660 shares during the period. Capital Management Corp VA owned about 0.23% of Supernus Pharmaceuticals worth $5,043,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Juncture Wealth Strategies LLC raised its position in Supernus Pharmaceuticals by 0.8% in the first quarter. Juncture Wealth Strategies LLC now owns 51,459 shares of the specialty pharmaceutical company’s stock worth $1,611,000 after buying an additional 433 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Supernus Pharmaceuticals by 4.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,107,007 shares of the specialty pharmaceutical company’s stock worth $27,952,000 after buying an additional 51,511 shares during the last quarter. Virginia Retirement Systems ET AL raised its position in Supernus Pharmaceuticals by 17.1% in the first quarter. Virginia Retirement Systems ET AL now owns 71,800 shares of the specialty pharmaceutical company’s stock worth $2,247,000 after buying an additional 10,500 shares during the last quarter. New York State Teachers Retirement System raised its position in Supernus Pharmaceuticals by 0.5% in the fourth quarter. New York State Teachers Retirement System now owns 77,035 shares of the specialty pharmaceutical company’s stock worth $1,945,000 after buying an additional 400 shares during the last quarter. Finally, Turner Investments LLC acquired a new position in Supernus Pharmaceuticals during the first quarter worth $219,000. Institutional investors and hedge funds own 94.39% of the company’s stock.

Supernus Pharmaceuticals, Inc. (NASDAQ SUPN) opened at 41.40 on Friday. Supernus Pharmaceuticals, Inc. has a one year low of $17.25 and a one year high of $44.95. The firm has a market cap of $2.10 billion, a PE ratio of 20.89 and a beta of 1.31. The stock has a 50 day moving average of $42.47 and a 200 day moving average of $34.12.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The firm had revenue of $75.83 million during the quarter, compared to analyst estimates of $68.54 million. On average, equities analysts forecast that Supernus Pharmaceuticals, Inc. will post $1.04 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Capital Management Corp VA Sells 4,660 Shares of Supernus Pharmaceuticals, Inc. (SUPN)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2017/08/12/supernus-pharmaceuticals-inc-supn-stake-decreased-by-capital-management-corp-va-updated-updated-updated.html.

SUPN has been the topic of several recent analyst reports. Cantor Fitzgerald boosted their price target on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the company a “buy” rating in a research note on Wednesday, July 5th. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Jefferies Group LLC set a $35.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 10th. Stifel Nicolaus reaffirmed a “buy” rating and set a $47.00 target price (up from $36.00) on shares of Supernus Pharmaceuticals in a research note on Tuesday, July 18th. Finally, Piper Jaffray Companies downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $46.00 target price on the stock. in a research note on Monday, July 17th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Supernus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $48.43.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 2,500 shares of the stock in a transaction on Friday, May 26th. The stock was sold at an average price of $35.90, for a total transaction of $89,750.00. Following the completion of the transaction, the vice president now directly owns 37,500 shares in the company, valued at $1,346,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 5,500 shares of the stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $34.90, for a total value of $191,950.00. Following the sale, the vice president now owns 43,887 shares in the company, valued at approximately $1,531,656.30. The disclosure for this sale can be found here. Insiders have sold 24,291 shares of company stock valued at $962,766 over the last quarter. Corporate insiders own 6.70% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit